Articles Tagged With:
Study Shows Increased Interest in New Male Contraceptive Gel
People are interested in a reversible and effective male contraceptive at a time when researchers are closer than ever to making this a reality, studies show.
Preterm Birth Predicts Lower Rate of Desired Permanent Contraception
A new study finds that patients who had preterm delivery were less likely to receive their desired permanent contraception when compared with patients who had at-term delivery.
Cervical Cancer Screening Is Important for All Women — Not Just Unvaccinated
Women who received the human papillomavirus (HPV) vaccine at the youngest age group of 9 to 12 years were less likely to participate in cervical cancer screening (a Pap test) than were those who received the vaccine during their teens and young adulthood, a new study finds.
Study Suggests Ways to Improve HPV Vaccination Rates
The most common sexually transmitted infection, human papillomavirus (HPV), also leads to a range of cancers in 10% of people infected with the virus. The most effective preventive measure is the HPV vaccine.
When Researching Youth Contraception, Include Young Voices in Study Design
Asking young people to contribute to research for improving contraceptive access can be a good strategy to improve contraception education and engagement that targets teenagers and young adults.
Who Is Most Likely to Seek Contraception from Publicly Supported Providers?
People with private health insurance typically obtain their contraceptive methods from private doctors’ offices, in-store clinics, or pharmacies, while just about everyone else relies on publicly funded health centers and family practice clinics for contraceptive care, a new study says.
Pediatric Procedural Sedation
Every acute care clinician needs to know and be familiar with the process of procedural sedation, medication selections, options, and contraindication for different procedures. The authors comprehensively review procedural sedation, emphasizing evidence-based choices.
Olezarsen Injection (Tryngolza)
The U.S. Food and Drug Aministration has approved olezarsen, a first-in-class drug to reduce triglycerides in adults with familial chylomicronemia syndrome. Olezarsen is an antisense oligonucleotide-directed inhibitor of apolipoprotein C-III messenger ribonucleic acid.
Noninferiority of Seven vs. 14 Days of Antibiotic Therapy for Bloodstream Infections
In this multinational, noninferiority trial that included more than 3,600 hospitalized patients with bloodstream infections from various pathogens and infectious syndromes, seven days of antibiotic therapy was noninferior to 14 days with respect to death from any cause by 90 days. Patients were excluded if they had severe immunosuppression or foci requiring prolonged treatment, or if their blood cultures yielded Staphylococcus aureus or possible contaminants. Various secondary outcomes were similar between the two groups.
Procalcitonin-Guided Care Leads to Shorter Duration of Antibiotics in Sepsis
In this multicenter, intervention-concealed, randomized clinical trial of 2,760 critically ill patients hospitalized with sepsis, the use of a daily procalcitonin-guided protocol resulted in shorter antibiotic duration as compared with standard care, without a significant difference in 28-day all-cause mortality. There was no significant difference in antibiotic duration between patients managed with a daily C-reactive protein-guided protocol and standard care, and the difference in all-cause mortality between these two groups was inconclusive.